Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record.

Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

Rabey, J. M., Sagi, I., Huberman, M., Melamed, E., Korczyn, A., Giladi, N., Inzelberg, R., Djaldetti, R., Klein, C., Berecz, G.·2000·Clinical Neuropharmacology

Abstract

Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities. The benefit of rasagiline as monotherapy in patients with early Parkinson's disease (PD) has already been reported. To evaluate the safety, tolerability, and clinical effect of rasagiline as adjunctive therapy to levodopa, a multicenter, double-blind, randomized, placebo-controlled, parallel-group study (0.5, 1, and 2 mg/d) was conducted for 12 weeks in 70 patients with PD (mean age, 57.4 y; mean disease duration, 5.7 y; 32 patients had motor fluctuations). A beneficial clinical effect was observed in fluctuating patients treated with rasagiline (all doses), expressed as a decrease in total Unified Parkinson's Disease Rating Scale (UPDRS) score (23.0% vs 8.5% in the placebo group). The treatment effect was still evident 6 weeks after drug discontinuation (in all doses). The safety and tolerability of rasagiline were good. Adverse events were no different than those of patients taking placebo. Almost complete platelet MAO-B inhibition was obtained at all rasagiline doses. This study has demonstrated that rasagiline (up to 2 mg/day) has a good safety profile and a beneficial clinical effect in fluctuating patients with PD when given as an add-on to chronic levodopa therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00002826-200011000-00005

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 178

Metadata

Authors
Rabey, J. M., Sagi, I., Huberman, M., Melamed, E., Korczyn, A., Giladi, N., Inzelberg, R., Djaldetti, R., Klein, C., & Berecz, G.
Venue
Clinical Neuropharmacology
Published
2000-11
Volume
23
Issue
6
Pages
324-330
ISSN
0362-5664 (ISSN-L)
OpenAlex
W2044368552
Cited by
178
References
0
FWCI
4.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa. https://app.cochat.ai/papers/10.1097/00002826-200011000-00005
The paper
Rabey, J. M., Sagi, I., Huberman, M., Melamed, E., Korczyn, A., Giladi, N., Inzelberg, R., Djaldetti, R., Klein, C., & Berecz, G. (2000). Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-200011000-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.